Related Experiment Video

Updated: May 16, 2026

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Rash to the mTOR inhibitor everolimus: systematic review and meta-analysis

Marigdalia K Ramirez-Fort1, Emily C Case, Alyx C Rosen

  • 1*Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA †Dermatology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York §Stony Brook University Medical School, Medical Oncology, Stony Brook, NY ‡Department of Dermatology, Hospital Santa Casa de Misericórdia de Curitiba/PUC-PR, Curitiba, PR, Brazil.

American Journal of Clinical Oncology
|December 18, 2012
PubMed
Abstract

Insights

Everolimus, an mTOR inhibitor, significantly increases the risk of developing a rash in cancer patients. Effective rash management is crucial for maintaining treatment adherence and quality of life.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Everolimus is an mTOR inhibitor used for various cancers.
  • Rash is a common adverse event associated with everolimus.
  • The incidence and risk of everolimus-induced rash require further investigation.

Purpose of the Study:

  • To systematically review and meta-analyze the literature.
  • To determine the incidence and risk of rash in patients treated with everolimus.

Main Methods:

  • Systematic review and meta-analysis of prospective phase II and III clinical trials.
  • Searched PubMed, Web of Science, and ASCO abstracts (1998-2011).
  • Included 2242 patients across 13 trials receiving 10 mg of everolimus daily.

Main Results:

  • The incidence of all-grade rash was 28.6% (95% CI, 20.8-38.0).
  • The incidence of high-grade rash was 1.0% (95% CI, 0.6-1.8).
  • Everolimus significantly increased the risk of all-grade rash (RR=3.853, P=0.000).

Conclusions:

  • Everolimus is associated with a significant risk of rash.
  • Rash management is critical for preventing dose modifications.
  • Effective management improves quality of life and clinical outcomes.

More Related Videos

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin10:21

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Published on: September 12, 2019

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.